Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XERS
Previous Symbol
CUSIPN/A
Phone844-445-5704
Debt
Debt-to-Equity Ratio0.33
Current Ratio16.55
Quick Ratio16.55
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.55 million
Price / Sales269.16
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees55
Outstanding Shares20,870,000
Market Cap$419.64 million
OptionableNot Optionable
Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions
What is Xeris Pharmaceuticals' stock symbol?
Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."
How were Xeris Pharmaceuticals' earnings last quarter?
Xeris Pharmaceuticals Inc (NASDAQ:XERS) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.78) by $0.07. The business had revenue of $0.58 million for the quarter, compared to the consensus estimate of $0.30 million. View Xeris Pharmaceuticals' Earnings History.
When is Xeris Pharmaceuticals' next earnings date?
What price target have analysts set for XERS?
4 brokerages have issued 12-month price objectives for Xeris Pharmaceuticals' stock. Their predictions range from $23.00 to $27.00. On average, they anticipate Xeris Pharmaceuticals' stock price to reach $24.50 in the next year. This suggests a possible upside of 22.6% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.
What is the consensus analysts' recommendation for Xeris Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.
What are Wall Street analysts saying about Xeris Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share." (12/4/2018)
- 2. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (10/17/2018)
Has Xeris Pharmaceuticals been receiving favorable news coverage?
News coverage about XERS stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Are investors shorting Xeris Pharmaceuticals?
Xeris Pharmaceuticals saw a decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,022,011 shares, a decline of 31.8% from the November 15th total of 1,499,120 shares. Based on an average daily volume of 32,070 shares, the days-to-cover ratio is currently 31.9 days. Approximately 6.1% of the company's shares are sold short. View Xeris Pharmaceuticals' Current Options Chain.
Who are some of Xeris Pharmaceuticals' key competitors?
Some companies that are related to Xeris Pharmaceuticals include Prestige Consumer Healthcare (PBH), Mallinckrodt (MNK), Biohaven Pharmaceutical (BHVN), Theravance Biopharma (TBPH), Wave Life Sciences (WVE), Enanta Pharmaceuticals (ENTA), The Medicines (MDCO), Cambrex (CBM), Vanda Pharmaceuticals (VNDA), Zai Lab (ZLAB), Tricida (TCDA), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Arrowhead Pharmaceuticals (ARWR) and Mirati Therapeutics (MRTX).
Who are Xeris Pharmaceuticals' key executives?
Xeris Pharmaceuticals' management team includes the folowing people:
- Mr. Paul R. Edick, Pres, CEO & Chairman (Age 62)
- Mr. John P. Shannon, Exec. VP & COO (Age 56)
- Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 54)
- Mr. Barry M. Deutsch, Chief Financial Officer (Age 53)
- Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
When did Xeris Pharmaceuticals IPO?
(XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.
When does the company's lock-up period expire?
Xeris Pharmaceuticals' lock-up period expires on Tuesday, December 18th. Xeris Pharmaceuticals had issued 5,700,000 shares in its IPO on June 21st. The total size of the offering was $85,500,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Who are Xeris Pharmaceuticals' major shareholders?
Xeris Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (8.80%), BlackRock Inc. (1.89%), Vanguard Group Inc (1.22%), Vanguard Group Inc. (1.22%), Perceptive Advisors LLC (0.96%) and Bank of New York Mellon Corp (0.07%). Company insiders that own Xeris Pharmaceuticals stock include James E Flynn and Palmetto Partners, Ltd. View Institutional Ownership Trends for Xeris Pharmaceuticals.
Which institutional investors are selling Xeris Pharmaceuticals stock?
Which institutional investors are buying Xeris Pharmaceuticals stock?
XERS stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc. and Bank of New York Mellon Corp. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include James E Flynn and Palmetto Partners, Ltd. View Insider Buying and Selling for Xeris Pharmaceuticals.
How do I buy shares of Xeris Pharmaceuticals?
Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xeris Pharmaceuticals' stock price today?
One share of XERS stock can currently be purchased for approximately $19.99.
How big of a company is Xeris Pharmaceuticals?
Xeris Pharmaceuticals has a market capitalization of $419.64 million and generates $1.55 million in revenue each year. Xeris Pharmaceuticals employs 55 workers across the globe.
What is Xeris Pharmaceuticals' official website?
How can I contact Xeris Pharmaceuticals?
Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]
MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
